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Abstract Human amylin (10 WM) significantly inhibited
RINm5F islet L-cell proliferation and evoked apoptosis asso-
ciated with typical degenerative ultrastructural changes and
DNA fragmentation, whereas rat amylin did not. Time course
analysis showed that human amylin elicited apoptosis in a
passage-dependent manner. Expression of the apoptosis-related
genes p53, bcl-2 and WAF1/CIP1 was examined using Northern
blots. mRNAs corresponding to p53 and to p21WAF=CIP1 were
remarkably increased following human amylin treatment,
whereas no change in bcl-2 was detected. Our data suggest a
role of p53 and p21 in human amylin-induced L-cell apoptosis.
Furthermore, cells with higher proliferative potential (lower
passage) were found to be more susceptible to apoptosis and to
induction of p53, suggesting that L-cells with different prolifera-
tion rates respond differently to human amylin, and that human
amylin may be more toxic to proliferating cells.
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1. Introduction
Amylin (also termed islet amyloid polypeptide, IAPP) is a
37-amino acid peptide, which is produced by pancreatic islet
L-cells and co-secreted with insulin in response to nutrient
stimuli [1,2]. Studies have demonstrated that amylin is the
key protein component of amyloid deposits found in the islets
of Langerhans in almost all patients with non-insulin-depend-
ent diabetes mellitus (NIDDM) [1,3]. A particular region of
the peptide between positions 20 and 29, termed the amyloid-
ogenic sequence, is thought to be responsible for amyloid
¢bril formation by the human peptide [4,5]. The sequence of
human amylin is identical in those with NIDDM and non-
a¡ected individuals, and the mechanism of amyloid deposition
in diabetes remains unclear at present. Furthermore, islet
amyloid formation is not found in diabetic rats, whose amylin
molecule has a di¡erent amino acid sequence in this molecular
region [6]. Evidence suggests that amyloid formation may be
related to hypersecretion of amylin associated with hypergly-
cemia acting in conjunction with other unknown factors
which may enhance pancreatic ¢bril formation [7,8].
Possible roles for amylin in the pathogenesis of diabetes
have been suggested [6,9,10]. Amylin has been implicated in
insulin resistance and abnormal insulin secretion, both of
which are characteristic of NIDDM [11,12]. The inhibitory
e¡ects of amylin on glycogen synthesis in isolated skeletal
muscles have also been reported [13,14]. In addition, a num-
ber of studies have suggested that human amylin may be toxic
to islet L-cells [10,15^17]. Ultra-structural analysis has indi-
cated that human amylin spontaneously aggregates into a L
pleated-sheet ¢bril structure in vitro, whereas no such ordered
structure has been observed for rat amylin [18,19]. It has been
suggested that contact of these ¢brils with L-cell membranes is
an event that can induce apoptosis [10,16], and that human
amylin may exert a direct toxic e¡ect on the pancreatic L-cell.
This toxic e¡ect of human amylin involves RNA and protein
synthesis [10]. Other studies have suggested that intermediate-
sized toxic amyloid particles, rather than mature amyloid de-
posits containing large (s 5 nm diameter) ¢brils, constitute
the toxic form of matter [16]. Furthermore, over-expression or
excessive secretion of human amylin may result in raised local
and/or circulating concentrations. Such an elevation in human
amylin concentrations could promote amyloid formation in-
side and/or outside L-cells [20,21]. Indeed, onset of diabetes,
associated with islet amyloid formation and decreased L-cell
mass, has been demonstrated in transgenic mice expressing
human amylin in their L-cells [7,8,22]. Over-expression of hu-
man amylin but not rat amylin in COS-1 cells also resulted in
intracellular amyloid formation which was associated with cell
death [23,24]. In the light of these observations, human amylin
could play a signi¢cant role in the progressive loss of L-cells in
NIDDM.
The underlying molecular mechanism by which human
amylin evokes L-cell death is not yet known. The evidence
reviewed above has suggested that apoptosis could be the
mode of cell death induced by human amylin in NIDDM.
Apoptosis is an active cell death process characterized by
cytoplasmic blebbing, apoptotic body formation, chromatin
condensation, breakup of the nucleus and DNA fragmenta-
tion [25]. A number of genes, including cellular oncogenes c-
myc, bcl-2, c-fos, c-jun and the tumor suppressor gene p53,
have been implicated in the control of apoptosis in mamma-
lian systems [25^27]. The tumor suppressor gene p53 encodes
a nuclear phosphoprotein that has been shown to play a crit-
ical role in regulating cell proliferation, the G1 cell cycle
checkpoint and apoptosis [28,29]. Over-expression of wild-
type p53 often leads to induction of cell cycle arrest and/or
apoptosis in a variety of cell types [26,30]. In response to
DNA damage or other forms of cellular injury, increased ex-
pression of p53 activates downstream target genes, such as
p21WAF1=CIP1 (p21), a cyclin-dependent kinase inhibitor
[28,29]. p21 inhibits kinase activity of various cyclin/cyclin-
dependent kinase complexes, which are key elements in cell
cycle progression, thereby preventing the transition from the
G1 to the S phase of the cell cycle and allowing time for repair
of damaged DNA [26,28]. Alternatively, p53 may repress the
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bcl-2 (B-cell lymphoma/leukemia) oncogene, another down-
stream e¡ector in the p53-dependent pathway of growth con-
trol [28]. Bcl-2 has been shown to inhibit apoptotic processes
in some cell systems [27,28,31]. Expression of bcl-2 can pre-
vent death of neurons deprived of nerve growth factor [31].
On the other hand, it has been shown that bcl-2 does not
protect against cytotoxic T-cell killing [32]. Therefore, bcl-2
cannot protect every type of cell against apoptosis.
The aim of this study was to better understand the mech-
anism by which human amylin evokes death in islet L-cells.
Here, we investigated the time course of induction of apopto-
sis by human amylin in a rat insulinoma cell line, RINm5F, to
determine whether any known apoptosis-related genes could
be implicated in this process.
2. Materials and methods
2.1. Cell culture and peptide treatment
RINm5F cells were cultured at 37‡C in a 5% CO2 atmosphere in
RPMI 1640 medium (Sigma) supplemented with 10% (v/v) fetal calf
serum, 290 mg/ml L-glutamine, 100 IU/ml penicillin, 100 Wg/ml strep-
tomycin and 2.5 mg/ml sodium hydrogen carbonate as described [33].
For amylin treatment, stock solutions (500 WM) were prepared by
dissolving synthetic human amylin (Lot ZL934, Bachem, CA) or rat
amylin (Lot ZM275, Bachem, CA) powder in water and incubating at
room temperature for 10 min. Cells (passage 26 and 53) were cultured
in 75 ml £asks to approximately 70% con£uence, after which human
or rat amylin was added to a ¢nal concentration of 10 WM. The
cultures were then incubated for further periods of 1, 2, 4, 8, 16 or
24 h, respectively. Untreated control cells were also cultured and
processed in an otherwise equivalent manner. For subsequent experi-
ments, cells were harvested by trypsinization and centrifugation.
2.2. Determination of cell proliferation rate
RINm5F cells (1U105) from passage 26 were seeded in 12 well
plates and cultured for 24 h. The cultures were then divided into three
groups: the ¢rst group (control) was cultured in the absence of amy-
lin, the second group was cultured in the continuous presence of 10
WM human amylin, whereas the third group was cultured in the con-
tinuous presence of 10 WM rat amylin. Cells were then harvested every
24 h by trypsinization and cell numbers counted with a hemocytom-
eter. Six cultures were used for experiments at each time point.
2.3. SEM analysis
The human amylin stock solution was incubated at room temper-
ature for 1 h to allow ¢bril formation. RINm5F cells (passage 35)
were cultured at 37‡C on 13 mm diameter glass coverslips (Deckgla«s-
er, West Germany) placed on the bottom of 24 well culture plates
(Linbro) until 80% con£uence, after which human amylin stock solu-
tion was added to give a ¢nal concentration of 10 WM; an equivalent
amount of water was added to control wells. Cells were further grown
at 37‡C for 22 h and then ¢xed for 3 h at room temperature with 3%
glutaraldehyde in 0.1 M Sorensen’s phosphate bu¡er (pH 7.2), follow-
ing which they were washed with 0.1 M Sorensen’s bu¡er (pH 7.2) for
3U10 min, then post-¢xed with 0.1% osmium tetroxide/0.1 M Soren-
sen’s phosphate bu¡er (pH 7.2) for 1 h at room temperature. Cells
were then serially dehydrated for 1U10 min with 30%, 50%, 70% and
90% ethanol, then 2U10 min with 100% ethanol, after which they
were critical point dried before specimen coverslips were mounted
onto SEM stubs. The specimens were viewed using a Phillips SEM
505 model scanning electron microscope.
2.4. Analysis of DNA fragmentation
RINm5F cell cultures were exposed to human or rat amylin for the
time periods described above. Genomic DNA was extracted with
DNAzol reagent (Gibco BRL) using a modi¢cation of the manufac-
turer’s protocol. Cells were digested in 2 ml DNAzol reagent for
10 min at room temperature, followed by phenol/chloroform/isoamyl
alcohol and chloroform/isoamyl alcohol extractions. DNA was then
precipitated with ethanol and resuspended in 10 mM Tris-HCl (pH
8.0)/1 mM EDTA. 5 Wg of each DNA sample was subjected to electro-
phoresis in a 1.2% agarose gel containing 0.1 Wg/ml ethidium bromide.
The DNA was then visualized under UV light. A 100 bp DNA ladder
(Gibco BRL) was run simultaneously to serve as a size marker.
2.5. Quantitative Northern blot analysis
RINm5F cell cultures were exposed to human or rat amylin for
various times as described above. Total RNA was isolated using an
RNeasy Midi kit (Qiagen). Northern blots were performed using
standard techniques as described [34]. 25 Wg of each RNA sample
was used for electrophoresis in a denaturing 1% agarose-formaldehyde
gel, then transferred onto a Hybond N nylon membrane (Amer-
sham). The membrane was then hybridized with various probes:
p53, p21 or bcl-2, respectively. Probes were labelled with [K-32P]dCTP
(Amersham) using a random primer labelling system (Gibco BRL).
Hybridizations were carried out at 65‡C for 18 h. The membranes
were washed at room temperature in 2USSC for 30 min, then at
65‡C in 1USSC for 15 min. mRNA levels were quanti¢ed using a
phosphor imager (BAS 2040, Fuji, Japan). All membranes were later
stripped and rehybridized with a GAPDH probe to normalize mRNA
levels. Three independent experiments were performed for each RNA
hybridization.
The cDNA probe for p53 was kindly provided by Dr. Evelyne May,
Laboratoire d’Oncologie Mole¤culaire, IRSC-CNRS, Villejuif Cedex,
France. The cDNA probes for p21 and bcl-2 were generated by RT-
PCR using the following primers: p21, 5P-TTGCGATGCGCTCAT-
GGCGAGC-3P and 5P-CGACAAGGCCACGTGGTCCTCC-3P, am-
plifying a 248 bp fragment; bcl-2, 5P-GTGGCCTTCTTTGAGTTC-
GGTGG-3P and 5P-AGGTCTGCTGACCTCACTTGTGG-3P, am-
plifying a 292 bp fragment.
3. Results and discussion
3.1. E¡ect of human amylin on RINm5F cell proliferation and
apoptosis
In order to understand the potential role of human amylin
in the induction of apoptosis and its possible contribution to
islet L-cell loss in NIDDM, the inhibitory e¡ect of human
amylin on cell proliferation was studied in RINm5F cells,
which are widely used as a model for functional studies of
pancreatic islet L-cells [35]. As shown in Fig. 1, cells (passage
26) were cultured in the presence or absence of human or rat
amylin and cell numbers determined over three days.
RINm5F cell proliferation was markedly inhibited by 10
WM human amylin. In the absence of peptide, the number
of control cells doubled approximately every 24 h in RPMI
1640 medium supplemented with 10% fetal calf serum. By
contrast, in the continuous presence of 10 WM human amylin,
Fig. 1. E¡ect of human amylin on RINm5F cell proliferation. Cells
(1U105) from passage 26 were seeded and cultured in 12-well plates.
From 24 h onwards, cells were incubated in the absence (a) or
presence of 10 WM human (b) or rat (U) amylin and cell numbers
determined at the time points indicated. Data represent mean þ
S.E.M. of six replicates at each time point.
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the number of cells increased by only about 10% after 24 h.
Interestingly, cells exposed to rat amylin retain a proliferative
capacity equivalent to that of untreated controls, indicating
that this peptide has little e¡ect compared with human amy-
lin.
Rat amylin di¡ers from the human peptide at six residues,
¢ve of which lie within the ‘amyloidogenic’ region,
amylin20ÿ29 [6,36]. Circular dichroism studies suggested that
human amylin adopts highly ordered stacking of L-sheet
structures in solution, whereas, by contrast, rat amylin dem-
onstrated no detectable L-structure in several solvents [37].
Aqueous solutions of synthetic human amylin spontaneously
form polymorphic ¢brils [5,19]. Recent studies with time-lapse
atomic force microscopy have shown that these solutions can
generate a previously uncharacterized proto¢bril, 2.4 nm in
diameter [38], which is likely to serve as the elemental form
underlying higher order assemblies containing coiled or rib-
bon-like ¢brillar structures [19]. Our current data, taken to-
gether with those of others [10], suggest that a form of matter
associated with the propensity of human amylin to form ag-
gregated states containing L-pleated sheet structures is likely
to underlie its ability to inhibit L-cell proliferation. However,
currently available data do not exclude the possibility that
sequence variations between human and rat amylin not asso-
ciated with their di¡erent tendencies to ¢bril formation might
also contribute to their di¡erent e¡ects on cell proliferation.
The observed smaller increase in cell population in human
amylin-treated cells in comparison to controls may result from
either a decline in the proliferation rate or an increase in cell
death, or both. To investigate the mechanism, RINm5F cells
were treated with 10 WM human amylin for 22 h, then sub-
jected to morphological analysis using scanning electron mi-
croscopy. The results, which are shown in Fig. 2, revealed
typical features common to cells undergoing apoptosis. We
observed the loss of microvilli from the cell surface and its
eventual smoothening, and the formation of blebs and pits on
the cell surface (Fig. 2B). These observations suggest that
RINm5F cells exposed to human amylin were undergoing
apoptosis. Under the same treatment conditions, apoptosis
of RINm5F cells has also been demonstrated by means of
the TUNEL (TdT-mediated dUTP-X nick end labelling) re-
action (G. MacGibbon and G.J.S. Cooper, unpublished data).
Furthermore, time course studies showed that induction of
apoptosis triggered by human amylin was also accompanied
by DNA fragmentation (Fig. 3). Fragmented DNA, which
appears as a series of bands when viewed on agarose gels,
has often been regarded as a biochemical hallmark of apop-
tosis. As shown in Fig. 3A, DNA extracted from RINm5F
cells, which had been exposed to human amylin for varying
amounts of time, exhibits a characteristic fragmentation lad-
der upon agarose gel electrophoresis. These distinct DNA
ladders were observed as early as 4 h following human amylin
treatment of cells at passage 26. However, rat amylin did not
induce apoptosis during equivalent exposures of up to 24 h,
indicating again that sequence di¡erences between human and
rat amylin and/or its aggregation propensity are likely to be
important factors in the induction of apoptosis. Equivalent
results have also been obtained using a second pancreatic islet
L-cell line, LTC6-F7 (J.-Z. Bai and G.J.S. Cooper, unpub-
lished data). Our ¢ndings are consistent with results reported
from studies using similar concentrations of human amylin
(5^20 WM) in primary cultures of rat and human islet L-cells
[10], indicating that the RINm5F cell line is a suitable cellular
model for studying the molecular mechanism of human amy-
lin-evoked apoptosis.
Apoptosis induced by human amylin was also studied in
RINm5F cells at a higher passage number (passage 53). As
shown in Fig. 3B, no distinct DNA ladders were observed
until 16 h after human amylin treatment began. This suggests
that the time course of induction of apoptosis is passage-de-
pendent. RINm5F cells from passage 53 proliferated with a
doubling time of about 36 h (data not shown) and thus have a
lower rate of proliferation, which may be due to a longer cell
cycle in comparison to cells from passage 26. Our observation
that apoptosis is delayed in more slowly proliferating cells
may suggest that susceptibility to human amylin-evoked
apoptosis is related to the rate of progression through the
Fig. 2. Scanning electron micrographs of RINm5F cells exposed to
human amylin. A: Untreated control cells with the arrows indicat-
ing the relative abundance of microvilli (m) on the cell surface. B:
Otherwise identically treated RINm5F cells. Arrows indicate blebs
(b) and pits (p) on the cell surface. Scale bars = 1 Wm.
Fig. 3. Determination of DNA fragmentation. DNA was extracted
from RINm5F cells from passage 26 (A) or passage 53 (B) at vari-
ous time points after treatment with human amylin (hA), rat amylin
(rA), or vehicle (water) control (co). M denotes the molecular size
markers (100 bp DNA ladder).
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cell cycle. In addition, that cells which have a higher prolifer-
ative potential (passage 26) are more susceptible to apoptosis,
may suggest that human amylin acts mainly on proliferating
cells.
3.2. Enhanced expression of p53 and p21WAF1=CIP1 in RINm5F
cells exposed to human amylin
In patients with NIDDM, the number of L-cells decreases
in association with increasing deposits of islet amyloid [39],
which increase with worsening clinical severity [40]. Recent
studies using an animal model of NIDDM (the Zucker dia-
betic fatty rat) have concluded that the decreased L-cell mass
in NIDDM is likely to be caused by an increased rate of cell
death by apoptosis, rather than a decline in the rate of L-cell
proliferation [41]. Therefore, identi¢cation of genes implicated
in human amylin-induced apoptosis could help to elucidate
the cause and progression of the disorder. Human amylin
may activate a subset of ‘death genes’ encoding speci¢c mo-
lecular components of the apoptotic machinery in islet L-cells.
Among the apoptosis-related genes, p53 has been shown to
act as a primary death-promoting gene, whereas bcl-2 is a
major apoptosis-suppressing gene; thus these genes could be
involved in the process of human amylin-evoked apoptosis.
The expression of p53 and bcl-2 in RINm5F cells treated with
human amylin was therefore examined in this study by North-
ern blot analysis. The results revealed that levels of p53
mRNA are up-regulated, but that bcl-2 expression remains
unchanged. As shown in Fig. 4A, the e¡ect of human amylin
on the accumulation of p53 mRNA appeared to be gradual
and was not detectable within the ¢rst 3 h. An increase in p53
mRNA was, however, detected after 4 h, reaching maximum
levels by 8 h. Thereafter the level of p53 mRNA remained
relatively high compared with controls, although a slight de-
crease had occurred by 24 h. Relative mRNA levels of p53
were calculated by normalizing to levels of GAPDH mRNA,
and by comparing amounts of p53 mRNA in amylin-treated
cells with those in corresponding untreated cells. In contrast,
bcl-2 mRNA was not increased over the period of 24 h (Fig.
4B). Rat amylin, by contrast, had no e¡ect on the expression
of either p53 or bcl-2. Our data indicate a role for p53 in
human amylin-evoked apoptosis in cultured RINm5F cells.
However, no signi¢cant change in bcl-2 expression was de-
Fig. 4. Northern blot analysis for p53 (A,D), bcl-2 (B) and p21WAF1=CIP1 (C) mRNA in RINm5F cells. Total RNA was isolated from RINm5F
cells (passage 26 or 53) treated with human (h) or rat (r) amylin, or vehicle (water) control at the time points indicated. Northern blot patterns
were reproducible in two further experiments. mRNA levels were quanti¢ed using a phosphor imager (BAS 2040). Results were normalized
against GAPDH mRNA levels and calculated relative to control at 1 h. Each data point represents the mean þ S.E.M. of three determinations.
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tected, suggesting that the contribution of bcl-2 to the induc-
tion of RINm5F cell apoptosis is insigni¢cant. The induction
of p53 mRNA in response to human amylin treatment coin-
cided with the initiation of apoptosis, as the DNA laddering
pattern became detectable at the same time point. It was also
found that the level of p53 mRNA in cells from passage 53
was not signi¢cantly increased until 16 h after human amylin
treatment (Fig. 4D), suggesting a passage- and cell cycle stage-
speci¢c role for p53 in RINm5F cell apoptosis. Thus, it is
likely that cells of the same lineage at di¡erent stages of mat-
uration are likely to have di¡erent degrees of human amylin
responsiveness.
p53 is one of the most frequently studied tumor-suppressing
genes. Any reagent or genotoxic stress that produces DNA
damage can cause a speci¢c cellular response whereby the
p53 protein accumulates to high levels [28]. This increase in
expression of p53 seems to be responsible for the arrest of
cells in the G1 phase of the cell cycle, presumably to enable
cells to repair their damaged DNA prior to the onset of DNA
synthesis and mitosis [29]. However, in the case of severe
DNA damage, p53 may promote apoptosis to eliminate cells
with compromised DNA. It has become increasingly evident
that cells must progress to late G1 or early S phase in the cell
cycle for apoptosis to occur [42]. This particular time in the
cell cycle is known as the p53 restriction point. To determine
whether human amylin-induced apoptosis in RINm5F cells is
preceded by a growth arrest, cell cycle analysis was performed
using a FACScan £ow cytometer. Cell cycle distribution was
determined by nuclear DNA content, as assayed by propidi-
um iodide staining. The results indeed revealed a reduction of
cells in the S/G2 phase 24 h after human amylin treatment
(data not shown), suggesting that entry of cells into the S
phase is hindered, thus provoking arrest in G1 of the cell
cycle.
The mechanism by which p53 elicits apoptosis is still unre-
solved. p53 functions as a transcription factor and is able to
bind in a sequence-speci¢c manner to DNA, activating the
transcription of several other target genes [28]. One of the
genes for which transcription is induced by p53 is the CDK-
inhibitor p21. p21 has been implicated in the induction of p53-
dependent or -independent apoptosis in various cell types in
response to a variety of agents [26,28] while other studies have
also suggested that p21 may protect from apoptosis or may
not even play a role in this process [43,44]. Therefore, the role
of p21 in DNA repair and apoptosis remains controversial.
p21 may exert an indirect in£uence to either induce or protect
from apoptosis. In this study, the expression of p21 mRNA in
human amylin-treated RINm5F cells was examined using
Northern blots. The results, shown in Fig. 4C, demonstrate
a signi¢cant increase of p21 mRNA, detected 4 h after human
amylin treatment, which reached a maximum level at 8 h and
was followed by a decrease at 16 and 24 h. In contrast, no
changes in p21 mRNA expression were observed up to 24 h
after rat amylin treatment. Our data suggest that enhanced
expression of p53 in response to human amylin treatment may
be followed by an increase of p21, resulting in decreased cell
proliferation rates. This decreased proliferation rate was due
to G1 arrest, as demonstrated by cell cycle analysis and oc-
currence of apoptosis.
It has been suggested that p53-mediated apoptosis is asso-
ciated with abrogation of growth arrest and continued pro-
gression through the cell cycle [42]. Our experiments show
that the level of p21 mRNA was increased at the same time
point as p53 mRNA and subsequently decreased to the un-
treated control levels by 24 h, whereas p53 mRNA levels
continued to remain relatively high (Fig. 4A,C,D). This ¢nd-
ing implies that RINm5F cells may be arrested prior to apop-
tosis. It is possible that the increases in p53 and p21 mRNA in
RINm5F cells occurring in response to human amylin initiate
growth arrest and give su⁄cient time for DNA repair. The
following decline in p21 mRNA may fail to elicit the response
of G1 arrest, thus allowing continued progression through the
cell cycle, leading to de¢cient DNA repair and subsequent
apoptosis.
Apoptosis plays an important role in normal cell homeo-
stasis and in the pathogenesis of a variety of human diseases
[45,46]. Amyloid deposits are associated with progressive fail-
ure of cellular function in many forms of amyloidosis other
than diabetes [45,47]. Neurodegenerative disorders, such as
Alzheimer’s disease (AD) and Parkinson’s disease, have been
characterized by increased levels of apoptosis resulting in ex-
cessive neuronal death [45]. Human amylin can assemble into
¢brillar structures similar to those of AL peptide (amyloid L
peptide), which accumulates in plaques in the brain of patients
with AD. These two peptides with di¡erent primary but sim-
ilar secondary structure are shown to be toxic to both islet L-
cells and cortical neurons [10,47]. Immunoblotting and immu-
nocytochemical studies also show that the level of p53 protein
was signi¢cantly increased in glial cells of AD brains as com-
pared to normal control brains [48]. The involvement of p53
in the apoptosis of islet RINm5F cells suggested that the
mechanism of cell death induced by human amylin in islet
L-cells may be similar to that evoked by AL peptide in AD
brain.
In summary, our data demonstrate that exogenously ap-
plied human amylin can inhibit RINm5F cell proliferation
by inducing growth arrest and apoptosis in a manner depend-
ent upon passage number. Activation of this apoptosis path-
way is associated with increased expression of p53 and p21.
Further studies will be required to clarify whether p53 is di-
rectly associated with processes involving its site-speci¢c DNA
binding capacity, or whether it is indirectly increased by other
factors induced by human amylin. Possible candidates could
include the nuclear factors known to activate transcription of
p53. In addition, the aqueous human amylin used for the cell
treatments in these studies contains a mixture of the soluble
amylin precursor, small proto¢brils, and higher order ¢brillar
structures [19,38]. Human amylin toxicity appears to vary
with aggregation state and is correlated with the acquisition
of L pleated-sheet structure, which in turn promotes human
amylin self-assembly and aggregation in solution [5,18,37].
Therefore, it will be of interest to further determine which
of these states of human amylin elicits L-cell death.
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